LinkedIn

 آمار

تعداد نشریات20
تعداد شماره‌ها1,135
تعداد مقالات10,372
تعداد مشاهده مقاله44,173,561
تعداد دریافت فایل اصل مقاله10,133,035
Hosseini-Asl, Seyed Mohammad Kazem, Mehrabani, Golnoush, Masoumi, Seyed Jalil. (1403). Key Focus Areas in Pouchitis Therapeutic Status: A Narrative Review. سامانه مدیریت نشریات علمی, 49(8), 472-486. doi: 10.30476/ijms.2024.100782.3326
Seyed Mohammad Kazem Hosseini-Asl; Golnoush Mehrabani; Seyed Jalil Masoumi. "Key Focus Areas in Pouchitis Therapeutic Status: A Narrative Review". سامانه مدیریت نشریات علمی, 49, 8, 1403, 472-486. doi: 10.30476/ijms.2024.100782.3326
Hosseini-Asl, Seyed Mohammad Kazem, Mehrabani, Golnoush, Masoumi, Seyed Jalil. (1403). 'Key Focus Areas in Pouchitis Therapeutic Status: A Narrative Review', سامانه مدیریت نشریات علمی, 49(8), pp. 472-486. doi: 10.30476/ijms.2024.100782.3326
Hosseini-Asl, Seyed Mohammad Kazem, Mehrabani, Golnoush, Masoumi, Seyed Jalil. Key Focus Areas in Pouchitis Therapeutic Status: A Narrative Review. سامانه مدیریت نشریات علمی, 1403; 49(8): 472-486. doi: 10.30476/ijms.2024.100782.3326

Key Focus Areas in Pouchitis Therapeutic Status: A Narrative Review

Iranian Journal of Medical Sciences
مقاله 2، دوره 49، شماره 8، آبان 2024، صفحه 472-486    اصل مقاله (318.3 K)
نوع مقاله: Review Article
شناسه دیجیتال (DOI): 10.30476/ijms.2024.100782.3326
نویسندگان
Seyed Mohammad Kazem Hosseini-Asl1؛ Golnoush Mehrabani2؛ Seyed Jalil Masoumi* 3، 4، 5
1Department of Internal Medicine, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
2School of Rehabilitation Medicine, University of Alberta, Edmonton, Alberta, Canada
3Nutrition Research Center, Department of Clinical Nutrition, School of Nutrition and Food Sciences, Shiraz University of Medical Science, Shiraz, Iran
4Gastroenterohepatology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
5Center for Cohort Study of SUMS Employees’ Health, Shiraz University of Medical Sciences, Shiraz, Iran
چکیده
Pouchitis, as the most common complication after ileal pouch-anal anastomosis (IPAA), has an incidence from 7% to 46%. Pouchitis treatment still represents one of the biggest gaps of knowledge in the treatment of diseases. This review has focused on achievements and challenges in the treatment of pouchitis. A combined assessment of symptoms, endoscopic findings, histologic results, quick biomarkers, and fecal calprotectin test were determined to be valuable diagnostic criteria. Conventional therapy was described as a modification of bacterial flora, mainly with antibiotics and more recently with probiotics such as bifidobacteria, lactobacilli, and streptococci. Other therapeutic approaches such as anti-tumor necrosis factor, infliximab, adalimumab, vedolizumab, ustekinumab, tacrolimus, tofacitinib, thiopurines, corticosteroids, prolyl hydroxylase–containing enzymes, povidone-iodine, dextrose spray, fecal microbiota transplantation, herbal medicines, and leukocyte apheresis have been discussed. Changes in dietary components, and administration of complementary and alternative medicine, probiotics, and fecal transplantation in addition to conventional therapies were also shown to affect the outcome of disease. Due to the potential significant impairment in quality of life caused by pouchitis, it is essential to address the gaps in knowledge for both patients and physicians in its treatment. Therefore, well-designed and adequately powered studies should assess the optimal treatment for pouchitis. 
کلیدواژه‌ها
Pouchitis؛ Risk factors؛ Diagnosis؛ Surgery؛ Treatment
سایر فایل های مرتبط با مقاله
مراجع
  1. Safarpour AR, Hosseini SV, Mehrabani D. Epidemiology of inflammatory bowel diseases in iran and Asia; a mini review. Iran J Med Sci. 2013;38:140-9. PubMed PMID: 24031103; PubMed Central PMCID: PMCPMC3771215.
  2. Hosseini-Asl SK, Mehrabani D, Karimi-Busheri F. Therapeutic Effect of Mesenchymal Stem Cells in Ulcerative Colitis: A Review on Achievements and Challenges. J Clin Med. 2020;9. doi: 10.3390/jcm9123922. PubMed PMID: 33287220; PubMed Central PMCID: PMCPMC7761671.
  3. Karjalainen EK, Renkonen-Sinisalo L, Satokari R, Mustonen H, Ristimaki A, Arkkila P, et al. Fecal Microbiota Transplantation in Chronic Pouchitis: A Randomized, Parallel, Double-Blinded Clinical Trial. Inflamm Bowel Dis. 2021;27:1766-72. doi: 10.1093/ibd/izab001. PubMed PMID: 33501942; PubMed Central PMCID: PMCPMC8528148.
  4. Ferrante M, Declerck S, De Hertogh G, Van Assche G, Geboes K, Rutgeerts P, et al. Outcome after proctocolectomy with ileal pouch-anal anastomosis for ulcerative colitis. Inflamm Bowel Dis. 2008;14:20-8. doi: 10.1002/ibd.20278. PubMed PMID: 17973304.
  5. Hata K, Okada S, Shinagawa T, Toshiaki T, Kawai K, Nozawa H. Meta-analysis of the association of extraintestinal manifestations with the development of pouchitis in patients with ulcerative colitis. BJS Open. 2019;3:436-44. doi: 10.1002/bjs5.50149. PubMed PMID: 31463422; PubMed Central PMCID: PMCPMC6706792.
  6. Barnes EL, Herfarth HH, Kappelman MD, Zhang X, Lightner A, Long MD, et al. Incidence, Risk Factors, and Outcomes of Pouchitis and Pouch-Related Complications in Patients With Ulcerative Colitis. Clin Gastroenterol Hepatol. 2021;19:1583-91 e4. doi: 10.1016/j.cgh.2020.06.035. PubMed PMID: 32585362; PubMed Central PMCID: PMCPMC8552292.
  7. Dubinsky V, Reshef L, Bar N, Keizer D, Golan N, Rabinowitz K, et al. Predominantly Antibiotic-resistant Intestinal Microbiome Persists in Patients With Pouchitis Who Respond to Antibiotic Therapy. Gastroenterology. 2020;158:610-24. doi: 10.1053/j.gastro.2019.10.001. PubMed PMID: 31605691.
  8. Shah H, Zezos P. Pouchitis: diagnosis and management. Curr Opin Gastroenterol. 2020;36:41-7. doi: 10.1097/MOG.0000000000000594. PubMed PMID: 31599752.
  9. Dipasquale V, Mattioli G, Arrigo S, Bramuzzo M, Strisciuglio C, Faraci S, et al. Pouchitis in pediatric ulcerative colitis: A multicenter study on behalf of Italian Society of Pediatric Gastroenterology, Hepatology and Nutrition. Dig Liver Dis. 2019;51:1551-6. doi: 10.1016/j.dld.2019.06.023. PubMed PMID: 31324473.
  10. Dai C, Jiang M, Sun MJ. The Effect of Smoking on the Risk of Pouchitis in Ulcerative Colitis Patients With Ileal Pouch-anal Anastomosis. Inflamm Bowel Dis. 2019;25:e42. doi: 10.1093/ibd/izy260. PubMed PMID: 30124837.
  11. Lander J, Richardson E, Kaufman A. Another RESIN for Pouchitis: Chronic Pouchitis With Erosion Secondary to Sodium Polystyrene Sulfonate Crystals. Am J Gastroenterol. 2018;113:327. doi: 10.1038/ajg.2017.466. PubMed PMID: 29535436.
  12. Weaver KN, Kochar B, Hansen JJ, Isaacs KL, Jain A, Sheikh SZ, et al. Chronic Antibiotic Dependent Pouchitis Is Associated With Older Age at the Time of Ileal Pouch Anal Anastomosis (J-pouch) Surgery. Crohns Colitis 360. 2019;1:29. doi: 10.1093/crocol/otz029. PubMed PMID: 31667470; PubMed Central PMCID: PMCPMC6798791.
  13. Kmeid M, Arker SH, Petchers A, Lukose G, Li H, Lee EC, et al. Appendiceal inflammation in colectomy is independently correlated with early pouchitis following ileal pouch anal anastomosis in ulcerative colitis and indeterminate colitis. Ann Diagn Pathol. 2021;55:151838. doi: 10.1016/j.anndiagpath.2021.151838. PubMed PMID: 34626936.
  14. Inoue E, Hata K, Kimura H, Yamaguchi K, Nojima M, Endo I, et al. Altered expression of microRNAs in patients with pouchitis after restorative proctocolectomy. Surg Today. 2017;47:1484-91. doi: 10.1007/s00595-017-1550-6. PubMed PMID: 28600635.
  15. Bresteau C, Amiot A, Kirchgesner J, de’Angelis N, Lefevre JH, Bouhnik Y, et al. Chronic pouchitis and Crohn’s disease of the pouch after ileal pouch-anal anastomosis: Incidence and risk factors. Dig Liver Dis. 2021;53:1128-35. doi: 10.1016/j.dld.2021.03.027. PubMed PMID: 33931341.
  16. Gao XH, Yu GY, Khan F, Li JQ, Stocchi L, Hull TL, et al. Greater Peripouch Fat Area on CT Image Is Associated with Chronic Pouchitis and Pouch Failure in Inflammatory Bowel Diseases Patients. Dig Dis Sci. 2020;65:3660-71. doi: 10.1007/s10620-020-06363-7. PubMed PMID: 32500285.
  17. Akiyama S, Rai V, Rubin DT. Pouchitis in inflammatory bowel disease: a review of diagnosis, prognosis, and treatment. Intest Res. 2021;19:1-11. doi: 10.5217/ir.2020.00047. PubMed PMID: 33138344; PubMed Central PMCID: PMCPMC7873408.
  18. Yang L, Bao J, Jiang Q, Yu DS, Zhong J. Lower fecal pH may be a novel indicator of pouchitis after IPAA in patients with FAP or metachronous Lynch syndrome. J Surg Oncol. 2019;120:1184-9. doi: 10.1002/jso.25699. PubMed PMID: 31478202.
  19. Zhu H, Wu XR, Queener E, Kiran RP, Remzi FH, Shen B. Clinical value of surveillance pouchoscopy in asymptomatic ileal pouch patients with underlying inflammatory bowel disease. Surg Endosc. 2013;27:4325-32. doi: 10.1007/s00464-013-3054-9. PubMed PMID: 23877758.
  20. Shen B, Achkar JP, Lashner BA, Ormsby AH, Remzi FH, Bevins CL, et al. Endoscopic and histologic evaluation together with symptom assessment are required to diagnose pouchitis. Gastroenterology. 2001;121:261-7. doi: 10.1053/gast.2001.26290. PubMed PMID: 11487535.
  21. Barreiro-de Acosta M, Gutierrez A, Rodriguez-Lago I, Espin E, Ferrer Bradley I, Marin-Jimenez I, et al. Recommendations of the Spanish Working Group on Crohn’s Disease and Ulcerative Colitis (GETECCU) on pouchitis in ulcerative colitis. Part 1: Epidemiology, diagnosis and prognosis. Gastroenterol Hepatol. 2019;42:568-78. doi: 10.1016/j.gastrohep.2019.08.001. PubMed PMID: 31606162.
  22. Samaan MA, Shen B, Mosli MH, Zou G, Sandborn WJ, Shackelton LM, et al. Reliability among central readers in the evaluation of endoscopic disease activity in pouchitis. Gastrointest Endosc. 2018;88:360-9. doi: 10.1016/j.gie.2018.04.2330. PubMed PMID: 29660321.
  23. Barreiro-de Acosta M, Marin-Jimenez I, Rodriguez-Lago I, Guarner F, Espin E, Ferrer Bradley I, et al. Recommendations of the Spanish Working Group on Crohn’s Disease and Ulcerative Colitis (GETECCU) on pouchitis in ulcerative colitis. Part 2: Treatment. Gastroenterol Hepatol. 2020;43:649-58. doi: 10.1016/j.gastrohep.2020.04.004. PubMed PMID: 32600917.
  24. Shen B, Achkar JP, Connor JT, Ormsby AH, Remzi FH, Bevins CL, et al. Modified pouchitis disease activity index: a simplified approach to the diagnosis of pouchitis. Dis Colon Rectum. 2003;46:748-53. doi: 10.1007/s10350-004-6652-8. PubMed PMID: 12794576.
  25. Lamb CA, Kennedy NA, Raine T, Hendy PA, Smith PJ, Limdi JK, et al. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut. 2019;68:s1-s106. doi: 10.1136/gutjnl-2019-318484. PubMed PMID: 31562236; PubMed Central PMCID: PMCPMC6872448.
  26. Kayal M, Ungaro R. Letter: is measurement of faecal biomarkers helpful for the early diagnosis and prediction of pouchitis after proctocolectomy for ulcerative colitis? Authors’ reply. Aliment Pharmacol Ther. 2020;51:190. doi: 10.1111/apt.15582. PubMed PMID: 31850582.
  27. McKechnie T, Lee Y, Kruse C, Ramji K, Springer JE, Wood T, et al. The role of fecal calprotectin in the diagnosis of acute pouchitis following IPAA for ulcerative colitis: a systematic clinical review. Int J Colorectal Dis. 2020;35:1619-28. doi: 10.1007/s00384-020-03669-w. PubMed PMID: 32617664.
  28. Fujimori A, Uchino M, Ikeuchi H, Masaki T. P227 Association between pouchitis and faecal calprotectin following restorative proctocolectomy in patients with ulcerative colitis. Journal of Crohn’s and Colitis. 2019;13:S210-S. doi: 10.1093/ecco-jcc/jjy222.351.
  29. Johnson MW, Maestranzi S, Duffy AM, Dewar DH, Ciclitira PJ, Sherwood RA, et al. Faecal M2-pyruvate kinase: a novel, noninvasive marker of ileal pouch inflammation. Eur J Gastroenterol Hepatol. 2009;21:544-50. doi: 10.1097/MEG.0b013e3283040cb3. PubMed PMID: 19300275.
  30. Matalon S, Elad H, Brazowski E, Santo E, Tulchinsky H, Dotan I. Serum alpha-1 antitrypsin: a noninvasive marker of pouchitis. Inflamm Bowel Dis. 2015;21:589-95. doi: 10.1097/MIB.0000000000000308. PubMed PMID: 25659085.
  31. Kitajima T, Okita Y, Kawamura M, Kondo S, Toiyama Y, Uchida K, et al. The relationship between preoperative T helper cytokines in the ileal mucosa and the pathogenesis of pouchitis. BMC Gastroenterol. 2020;20:277. doi: 10.1186/s12876-020-01421-w. PubMed PMID: 32811425; PubMed Central PMCID: PMCPMC7437011.
  32. Nishida Y, Hosomi S, Yamagami H, Fujimoto K, Nakata R, Itani S, et al. Novel prognostic biomarkers of pouchitis after ileal pouch-anal anastomosis for ulcerative colitis: Neutrophil-to-lymphocyte ratio. PLoS One. 2020;15:e0241322. doi: 10.1371/journal.pone.0241322. PubMed PMID: 33104762; PubMed Central PMCID: PMCPMC7588073.
  33. Morilla I, Uzzan M, Cazals-Hatem D, Colnot N, Panis Y, Nancey S, et al. Computational Learning of microRNA-Based Prediction of Pouchitis Outcome After Restorative Proctocolectomy in Patients With Ulcerative Colitis. Inflamm Bowel Dis. 2021;27:1653-60. doi: 10.1093/ibd/izab030. PubMed PMID: 33609036.
  34. Dalal RL, Shen B, Schwartz DA. Management of Pouchitis and Other Common Complications of the Pouch. Inflamm Bowel Dis. 2018;24:989-96. doi: 10.1093/ibd/izy020. PubMed PMID: 29688472.
  35. Gionchetti P, Rizzello F, Venturi A, Brigidi P, Matteuzzi D, Bazzocchi G, et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology. 2000;119:305-9. doi: 10.1053/gast.2000.9370. PubMed PMID: 10930365.
  36. Madden MV, McIntyre AS, Nicholls RJ. Double-blind crossover trial of metronidazole versus placebo in chronic unremitting pouchitis. Dig Dis Sci. 1994;39:1193-6. doi: 10.1007/BF02093783. PubMed PMID: 8200250.
  37. Emile SH, Horesh N, Freund MR, Garoufalia Z, Gefen R, Khan SM, et al. A Systematic Review and Meta-analysis of Randomized Clinical Trials on the Prevention and Treatment of Pouchitis after Ileoanal Pouch Anastomosis. J Gastrointest Surg. 2023;27:2650-60. doi: 10.1007/s11605-023-05841-3. PubMed PMID: 37815701.
  38. Alphonsus L, De Silva TA, Ma C, MacDonald JK, Hanzel J, Beaton M, et al. Systematic review and meta-analysis of randomised controlled trials: Medical therapies for the treatment and prevention of pouchitis. Aliment Pharmacol Ther. 2023;58:268-82. doi: 10.1111/apt.17568. PubMed PMID: 37246609.
  39. Shen B, Achkar JP, Lashner BA, Ormsby AH, Remzi FH, Brzezinski A, et al. A randomized clinical trial of ciprofloxacin and metronidazole to treat acute pouchitis. Inflamm Bowel Dis. 2001;7:301-5. doi: 10.1097/00054725-200111000-00004. PubMed PMID: 11720319.
  40. Li Y, Qian J, Queener E, Shen B. Risk factors and outcome of PCR-detected Clostridium difficile infection in ileal pouch patients. Inflamm Bowel Dis. 2013;19:397-403. doi: 10.1097/MIB.0b013e318280fcb9. PubMed PMID: 23328770.
  41. Nygaard K, Bergan T, Bjorneklett A, Hoverstad T, Lassen J, Aase S. Topical metronidazole treatment in pouchitis. Scand J Gastroenterol. 1994;29:462-7. doi: 10.3109/00365529409096839. PubMed PMID: 8036463.
  42. Kayal M, Tixier E, Plietz M, Radcliffe M, Rizvi A, Riggs A, et al. Clostridioides Difficile Infection Is a Rare Cause of Infectious Pouchitis. Inflamm Intest Dis. 2020;5:59-64. doi: 10.1159/000505658. PubMed PMID: 32596255; PubMed Central PMCID: PMCPMC7315207.
  43. Scaioli E, Sartini A, Liverani E, Digby RJ, Ugolini G, Rosati G, et al. Sulfasalazine in Prevention of Pouchitis After Proctocolectomy with Ileal Pouch-Anal Anastomosis for Ulcerative Colitis. Dig Dis Sci. 2017;62:1016-24. doi: 10.1007/s10620-017-4454-9. PubMed PMID: 28110377.
  44. Li KY, Wang X, Liu G, He AQ, Zheng ZC, Zhao XY, et al. A New Rat Model of Pouchitis After Proctocolectomy and Ileal Pouch-Anal Anastomosis Using 2,4,6-Trinitrobenzene Sulfonic Acid. J Gastrointest Surg. 2021;25:1524-33. doi: 10.1007/s11605-020-04642-2. PubMed PMID: 32424688.
  45. Davanas C. Off-label medicine use/prescribing controversies through patients’ eyes/”rights”: the example of povidone-iodine enemas/suppositories for “terminal” pouchitis. Pan Afr Med J. 2019;33:155. doi: 10.11604/pamj.2019.33.155.19222. PubMed PMID: 31565117; PubMed Central PMCID: PMCPMC6756802.
  46. Huguet M, Pereira B, Goutte M, Goutorbe F, Dubois A, Bommelaer G, et al. Systematic Review With Meta-Analysis: Anti-TNF Therapy in Refractory Pouchitis and Crohn’s Disease-Like Complications of the Pouch After Ileal Pouch-Anal Anastomosis Following Colectomy for Ulcerative Colitis. Inflamm Bowel Dis. 2018;24:261-8. doi: 10.1093/ibd/izx049. PubMed PMID: 29361101.
  47. Herfarth HH, Long MD, Isaacs KL. Use of Biologics in Pouchitis: A Systematic Review. J Clin Gastroenterol. 2015;49:647-54. doi: 10.1097/MCG.0000000000000367. PubMed PMID: 26084005; PubMed Central PMCID: PMCPMC4532631.
  48. Ferrante M, D’Haens G, Dewit O, Baert F, Holvoet J, Geboes K, et al. Efficacy of infliximab in refractory pouchitis and Crohn’s disease-related complications of the pouch: a Belgian case series. Inflamm Bowel Dis. 2010;16:243-9. doi: 10.1002/ibd.21037. PubMed PMID: 19637335.
  49. Barreiro-de Acosta M, Garcia-Bosch O, Souto R, Manosa M, Miranda J, Garcia-Sanchez V, et al. Efficacy of infliximab rescue therapy in patients with chronic refractory pouchitis: a multicenter study. Inflamm Bowel Dis. 2012;18:812-7. doi: 10.1002/ibd.21821. PubMed PMID: 21826765.
  50. Koumaki D, Orfanoudaki E, Machaira A, Lagoudaki E, Krasagakis K, Koutroubakis IE. Pyoderma gangrenosum associated with chronic refractory pouchitis: a case successfully treated with infliximab. Ann Gastroenterol. 2020;33:433-5. doi: 10.20524/aog.2020.0500. PubMed PMID: 32624666; PubMed Central PMCID: PMCPMC7315701.
  51. Yanagi M, Komura T, Kagaya T, Yoshio T, Nishino M, Orita N, et al. A case of refractory pouchitis complicated by cytomegalovirus infection requiring administration of ganciclovir and infliximab. Clin J Gastroenterol. 2021;14:181-6. doi: 10.1007/s12328-020-01289-z. PubMed PMID: 33475967.
  52. Uchino M, Ikeuchi H, Bando T, Hirata A, Chohno T, Sasaki H, et al. Association between serum tumor necrosis factor-alpha level and the efficacy of infliximab for refractory pouchitis after restorative proctocolectomy in patients with ulcerative colitis. J Anus Rectum Colon. 2017;1:106-11. doi: 10.23922/jarc.2016-008. PubMed PMID: 31583309; PubMed Central PMCID: PMCPMC6768686.
  53. Uzzan M, Nachury M, Amiot A, Peyrin-Biroulet L, Kirchgesner J, Bouhnik Y, et al. Effectiveness and safety of tofacitinib in patients with chronic pouchitis multirefractory to biologics. Dig Liver Dis. 2023;55:1158-60. doi: 10.1016/j.dld.2023.04.028. PubMed PMID: 37248123.
  54. Barreiro-de Acosta M, Garcia-Bosch O, Gordillo J, Manosa M, Menchen L, Souto R, et al. Efficacy of adalimumab rescue therapy in patients with chronic refractory pouchitis previously treated with infliximab: a case series. Eur J Gastroenterol Hepatol. 2012;24:756-8. doi: 10.1097/MEG.0b013e3283525a7b. PubMed PMID: 22395225.
  55. Bozon A, Debourdeau A, Boivineau L. Liver Transplantation for Fulminant Herpes Simplex Hepatitis in a Patient Treated With Adalimumab for Chronic Pouchitis. J Crohns Colitis. 2020;14:1649. doi: 10.1093/ecco-jcc/jjaa072. PubMed PMID: 32267914.
  56. Kjaer MD, Qvist N, Nordgaard-Lassen I, Christensen LA, Kjeldsen J. Adalimumab in the treatment of chronic pouchitis. A randomized double-blind, placebo-controlled trial. Scand J Gastroenterol. 2019;54:188-93. doi: 10.1080/00365521.2019.1569718. PubMed PMID: 30739519.
  57. Gionchetti P, Calabrese C, Calafiore A, Pratico C, Poggioli G, Laureti S, et al. Oral beclomethasone dipropionate in chronic refractory pouchitis. J Crohns Colitis. 2014;8:649-53. doi: 10.1016/j.crohns.2013.12.001. PubMed PMID: 24394806.
  58. Navaneethan U, Venkatesh PG, Bennett AE, Patel V, Hammel J, Kiran RP, et al. Impact of budesonide on liver function tests and gut inflammation in patients with primary sclerosing cholangitis and ileal pouch anal anastomosis. J Crohns Colitis. 2012;6:536-42. doi: 10.1016/j.crohns.2011.10.011. PubMed PMID: 22398056.
  59. Sambuelli A, Boerr L, Negreira S, Gil A, Camartino G, Huernos S, et al. Budesonide enema in pouchitis--a double-blind, double-dummy, controlled trial. Aliment Pharmacol Ther. 2002;16:27-34. doi: 10.1046/j.1365-2036.2002.01139.x. PubMed PMID: 11856075.
  60. Zullow S, Fazelat A, Farraye FA. Central Serous Chorioretinopathy in a Patient with Ulcerative Colitis with Pouchitis on Budesonide-EC. Inflamm Bowel Dis. 2017;23:E19. doi: 10.1097/MIB.0000000000001091. PubMed PMID: 28328626.
  61. Landy J, Al-Hassi HO, Ronde E, English NR, Mann ER, Bernardo D, et al. Innate immune factors in the development and maintenance of pouchitis. Inflamm Bowel Dis. 2014;20:1942-9. doi: 10.1097/MIB.0000000000000182. PubMed PMID: 25222658.
  62. Travis S, Silverberg MS, Danese S, Gionchetti P, Lowenberg M, Jairath V, et al. Vedolizumab for the Treatment of Chronic Pouchitis. N Engl J Med. 2023;388:1191-200. doi: 10.1056/NEJMoa2208450. PubMed PMID: 36988594.
  63. Jairath V, Feagan BG, Silverberg MS, Danese S, Gionchetti P, Löwenberg M, et al. OP08 Mucosal healing with vedolizumab in inflammatory bowel disease patients with chronic pouchitis: Evidence from EARNEST, a randomized, double-blind, placebo-controlled trial. Journal of Crohn’s and Colitis. 2023;17:i13-i4. doi: 10.1093/ecco-jcc/jjac190.0008.
  64. Bar F, Kuhbacher T, Dietrich NA, Krause T, Stallmach A, Teich N, et al. Vedolizumab in the treatment of chronic, antibiotic-dependent or refractory pouchitis. Aliment Pharmacol Ther. 2018;47:581-7. doi: 10.1111/apt.14479. PubMed PMID: 29266360.
  65. Gregory M, Weaver KN, Hoversten P, Hicks SB, Patel D, Ciorba MA, et al. Efficacy of Vedolizumab for Refractory Pouchitis of the Ileo-anal Pouch: Results From a Multicenter US Cohort. Inflamm Bowel Dis. 2019;25:1569-76. doi: 10.1093/ibd/izz030. PubMed PMID: 30810748; PubMed Central PMCID: PMCPMC6939832.
  66. Coletta M, Paroni M, Caprioli F. Successful Treatment With Vedolizumab in a Patient With Chronic Refractory Pouchitis and Primary Sclerosing Cholangitis. J Crohns Colitis. 2017;11:1507-8. doi: 10.1093/ecco-jcc/jjx090. PubMed PMID: 29106505.
  67. Mir F, Yousef MH, Partyka EK, Tahan V. Successful treatment of chronic refractory pouchitis with vedolizumab. Int J Colorectal Dis. 2017;32:1517-8. doi: 10.1007/s00384-017-2854-0. PubMed PMID: 28698974.
  68. Orfanoudaki E, Foteinogiannopoulou K, Koutroubakis IE. Use of vedolizumab in a patient with chronic and refractory pouchitis. Ann Gastroenterol. 2018;31:379. doi: 10.20524/aog.2018.0243. PubMed PMID: 29720865; PubMed Central PMCID: PMCPMC5924862.
  69. Khan F, Gao XH, Singh A, Philpott JR, Shen B. Vedolizumab in the treatment of Crohn’s disease of the pouch. Gastroenterol Rep (Oxf). 2018;6:184-8. doi: 10.1093/gastro/goy014. PubMed PMID: 30151202; PubMed Central PMCID: PMCPMC6101609.
  70. Ribaldone DG, Pellicano R, Saracco GM, Morino M, Astegiano M. Vedolizumab for treatment of chronic refractory pouchitis: a systematic review with pool analysis. Rev Esp Enferm Dig. 2020;112:59-63. doi: 10.17235/reed.2019.6336/2019. PubMed PMID: 31823641.
  71. Cakir OO. Effectiveness of vedolizumab treatment in two different anti-tumor necrosis factor alpha refractory pouchitis: A case report. World J Clin Cases. 2019;7:2316-21. doi: 10.12998/wjcc.v7.i16.2316. PubMed PMID: 31531325; PubMed Central PMCID: PMCPMC6718792.
  72. Verstockt B, Claeys C, De Hertogh G, Van Assche G, Wolthuis A, D’Hoore A, et al. Outcome of biological therapies in chronic antibiotic-refractory pouchitis: A retrospective single-centre experience. United European Gastroenterol J. 2019;7:1215-25. doi: 10.1177/2050640619871797. PubMed PMID: 31700634; PubMed Central PMCID: PMCPMC6826521.
  73. Martins D, Ministro P, Silva A. Refractory Chronic Pouchitis and Autoimmune Hemolytic Anemia Successfully Treated with Vedolizumab. GE Port J Gastroenterol. 2018;25:340-1. doi: 10.1159/000486803. PubMed PMID: 30480056; PubMed Central PMCID: PMCPMC6243957.
  74. Bethge J, Meffert S, Ellrichmann M, Conrad C, Nikolaus S, Schreiber S. Combination therapy with vedolizumab and etanercept in a patient with pouchitis and spondylarthritis. BMJ Open Gastroenterol. 2017;4:e000127. doi: 10.1136/bmjgast-2016-000127. PubMed PMID: 28243458; PubMed Central PMCID: PMCPMC5306500.
  75. Singh A, Khan F, Lopez R, Shen B, Philpott J. Vedolizumab for chronic antibiotic-refractory pouchitis. Gastroenterol Rep (Oxf). 2019;7:121-6. doi: 10.1093/gastro/goz001. PubMed PMID: 30976425; PubMed Central PMCID: PMCPMC6454848.
  76. Ollech JE, Rubin DT, Glick L, Weisshof R, El Jurdi K, Israel A, et al. Ustekinumab Is Effective for the Treatment of Chronic Antibiotic-Refractory Pouchitis. Dig Dis Sci. 2019;64:3596-601. doi: 10.1007/s10620-019-05697-1. PubMed PMID: 31187322; PubMed Central PMCID: PMCPMC6858501.
  77. Outtier A, Louis E, Dewit O, Schops G, Verstockt B, Sabino J, et al. P521 Effectiveness of ustekinumab as therapy for chronic antibiotic refractory pouchitis. Journal of Crohn’s and Colitis. 2023;17:i649-i50. doi: 10.1093/ecco-jcc/jjac190.0651.
  78. Weaver KN, Gregory M, Syal G, Hoversten P, Hicks SB, Patel D, et al. Ustekinumab Is Effective for the Treatment of Crohn’s Disease of the Pouch in a Multicenter Cohort. Inflamm Bowel Dis. 2019;25:767-74. doi: 10.1093/ibd/izy302. PubMed PMID: 30295784.
  79. Peter J, Zeitz J, Stallmach A. Ustekinumab Rescue Therapy in a Patient With Chronic Refractory Pouchitis. J Crohns Colitis. 2018;12:1008-9. doi: 10.1093/ecco-jcc/jjy037. PubMed PMID: 29659775.
  80. Salem G, Ding K, Sakuraba A, Cohen R. Role of topical tacrolimus in the management of proctitis, perianal manifestations in Crohn’s disease, and chronic pouchitis: a systematic review. J Investig Med. 2021. doi: 10.1136/jim-2020-001699. PubMed PMID: 33622709.
  81. Gundling F, Tiller M, Agha A, Schepp W, Iesalnieks I. Successful autologous fecal transplantation for chronic diversion colitis. Tech Coloproctol. 2015;19:51-2. doi: 10.1007/s10151-014-1220-2. PubMed PMID: 25300242.
  82. Uchino M, Ikeuchi H, Matsuoka H, Bando T, Hida N, Nakamura S, et al. Topical tacrolimus therapy for antibiotic-refractory pouchitis. Dis Colon Rectum. 2013;56:1166-73. doi: 10.1097/DCR.0b013e31829ebd83. PubMed PMID: 24022534.
  83. Syal G, Mishkin DS, Banty A, Lee S, Fontelera N, Hampton M, et al. Effectiveness of Oral Tofacitinib in Chronic Pouchitis: A Prospective, Open-Label Pilot Study. Inflamm Bowel Dis. 2023. doi: 10.1093/ibd/izad191. PubMed PMID: 37898112.
  84. Okano S, Yoshimura N, Sako M, Takazoe M. A case of refractory chronic pouchitis successfully treated with tofacitinib. Clin J Gastroenterol. 2020;13:560-3. doi: 10.1007/s12328-020-01108-5. PubMed PMID: 32130659.
  85. Sedano R, Nunez P, Quera R. Diagnostic and Management Approach to Pouchitis in Inflammatory Bowel Disease. Arq Gastroenterol. 2020;57:100-6. doi: 10.1590/S0004-2803.202000000-17. PubMed PMID: 32294743.
  86. Greuter T, Rogler G. Alicaforsen in the treatment of pouchitis. Immunotherapy. 2017;9:1143-52. doi: 10.2217/imt-2017-0085. PubMed PMID: 29067882.
  87. Harnoss JM, Gebhardt JM, Radhakrishnan P, Leowardi C, Burmeister J, Halligan DN, et al. Prolyl Hydroxylase Inhibition Mitigates Pouchitis. Inflamm Bowel Dis. 2020;26:192-205. doi: 10.1093/ibd/izz218. PubMed PMID: 31618435.
  88. Watanabe C, Hokari R, Miura S. Chronic antibiotic-refractory diversion pouchitis successfully treated with leukocyteapheresis. Ther Apher Dial. 2014;18:644-5. doi: 10.1111/1744-9987.12175. PubMed PMID: 24571541.
  89. Maulahela H, Utari AP, Pribadi RR, Muzelina VN, Nursyirwan SA. Hypertonic dextrose spray as topical endoscopic hemostasis for non-variceal upper gastrointestinal bleeding. International Journal of Gastrointestinal Intervention. 2023;12:93-8. doi: 10.18528/ijgii220036.
  90. Nyabanga CT, Shen B. Endoscopic Treatment of Bleeding Diversion Pouchitis with High-Concentration Dextrose Spray. ACG Case Rep J. 2017;4:e51. doi: 10.14309/crj.2017.51. PubMed PMID: 28377939; PubMed Central PMCID: PMCPMC5371723.
  91. Tian C, Mehta P, Shen B. Endoscopic Therapy of Bleeding from Radiation Enteritis with Hypertonic Glucose Spray. ACG Case Rep J. 2014;1:181-3. doi: 10.14309/crj.2014.45. PubMed PMID: 26157869; PubMed Central PMCID: PMCPMC4435317.
  92. Barnes EL, Agrawal M, Syal G, Ananthakrishnan AN, Cohen BL, Haydek JP, et al. AGA Clinical Practice Guideline on the Management of Pouchitis and Inflammatory Pouch Disorders. Gastroenterology. 2024;166:59-85. doi: 10.1053/j.gastro.2023.10.015. PubMed PMID: 38128971; PubMed Central PMCID: PMCPMC11163976.
  93. Kousgaard SJ. Faecal Microbiota Transplantation for Treatment of Chronic Pouchitis: Role of Gut Microbiota in Disease Mechanism and Treatment of Pouchitis. Udgivet Aalborg Universitetsforlag. 2023. doi: 10.54337/aau561823572.
  94. Gionchetti P, Rizzello F, Helwig U, Venturi A, Lammers KM, Brigidi P, et al. Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. Gastroenterology. 2003;124:1202-9. doi: 10.1016/s0016-5085(03)00171-9. PubMed PMID: 12730861.
  95. Gosselink MP, Schouten WR, van Lieshout LM, Hop WC, Laman JD, Ruseler-van Embden JG. Delay of the first onset of pouchitis by oral intake of the probiotic strain Lactobacillus rhamnosus GG. Dis Colon Rectum. 2004;47:876-84. doi: 10.1007/s10350-004-0525-z. PubMed PMID: 15108026.
  96. Xu YY, Zhang YY, He AQ, Li KY, Gao SY, Liu G. Lactobacillus acidophilus alleviates pouchitis after ileal pouch-anal anastomosis in rats. World J Gastroenterol. 2017;23:4735-43. doi: 10.3748/wjg.v23.i26.4735. PubMed PMID: 28765694; PubMed Central PMCID: PMCPMC5514638.
  97. Pronio A, Montesani C, Butteroni C, Vecchione S, Mumolo G, Vestri A, et al. Probiotic administration in patients with ileal pouch-anal anastomosis for ulcerative colitis is associated with expansion of mucosal regulatory cells. Inflamm Bowel Dis. 2008;14:662-8. doi: 10.1002/ibd.20369. PubMed PMID: 18240282.
  98. Singh S, Stroud AM, Holubar SD, Sandborn WJ, Pardi DS. Treatment and prevention of pouchitis after ileal pouch-anal anastomosis for chronic ulcerative colitis. Cochrane Database Syst Rev. 2015:CD001176. doi: 10.1002/14651858.CD001176.pub3. PubMed PMID: 26593456; PubMed Central PMCID: PMCPMC4917283.
  99. Shen B, Brzezinski A, Fazio VW, Remzi FH, Achkar JP, Bennett AE, et al. Maintenance therapy with a probiotic in antibiotic-dependent pouchitis: experience in clinical practice. Aliment Pharmacol Ther. 2005;22:721-8. doi: 10.1111/j.1365-2036.2005.02642.x. PubMed PMID: 16197493.
  100. Gionchetti P, Rizzello F, Morselli C, Poggioli G, Tambasco R, Calabrese C, et al. High-dose probiotics for the treatment of active pouchitis. Dis Colon Rectum. 2007;50:2075-82; discussion 82-4. doi: 10.1007/s10350-007-9068-4. PubMed PMID: 17934776.
  101. Fliss Isakov N, Kornblum J, Zemel M, Cohen NA, Hirsch A, Maharshak N. The Effect of the Crohn’s Disease Exclusion Diet on Patients With Pouch Inflammation: An Interventional Pilot Study. Clin Gastroenterol Hepatol. 2023;21:1654-6. doi: 10.1016/j.cgh.2022.03.049. PubMed PMID: 35447313.
  102. Godny L, Maharshak N, Reshef L, Goren I, Yahav L, Fliss-Isakov N, et al. Fruit Consumption is Associated with Alterations in Microbial Composition and Lower Rates of Pouchitis. J Crohns Colitis. 2019;13:1265-72. doi: 10.1093/ecco-jcc/jjz053. PubMed PMID: 30828722.
  103. Kousgaard SJ, Nielsen HL, Kirk KF, Thorlacius-Ussing O. Consumption of yoghurt favours remission after faecal microbiota transplantation for chronic pouchitis. Int J Colorectal Dis. 2020;35:1955-8. doi: 10.1007/s00384-020-03648-1. PubMed PMID: 32504332.
  104. Fritsch J, Abreu MT. Exposing the Achilles Heel of Antibiotic Therapy for Pouchitis Using Microbial Function and Composition. Gastroenterology. 2020;158:470-2. doi: 10.1053/j.gastro.2019.11.303. PubMed PMID: 31863743.
  105. Ardalan ZS, Sparrow M, Gibson PR. The Importance of Accurate Phenotyping and Pouchitis Risk and Dietary Assessment When Investigating the Microbial Factors Behind Antibiotic-Dependent Pouchitis. Gastroenterology. 2020;159:399-400. doi: 10.1053/j.gastro.2020.02.065. PubMed PMID: 32234300.
  106. Kahan T, Chandan S, Khan SR, Deliwala S, Chang S, Axelrad J, et al. Safety And Efficacy of Fecal Microbiota Transplant (FMT) In Chronic Pouchitis–A Systematic Review with Meta-analysis. Gastro hep advances. 2023;2:843-52. doi: 10.1016/j.gastha.2023.04.005.
  107. Zaman S, Akingboye A, Mohamedahmed AYY, Peterknecht E, Bhattacharya P, El-Asrag ME, et al. Faecal Microbiota Transplantation [FMT] in the Treatment of Chronic Refractory Pouchitis: A Systematic Review and Meta-analysis. J Crohns Colitis. 2024;18:144-61. doi: 10.1093/ecco-jcc/jjad120. PubMed PMID: 37450947; PubMed Central PMCID: PMCPMC10821709.
  108. Nishida A, Imaeda H, Inatomi O, Bamba S, Sugimoto M, Andoh A. The efficacy of fecal microbiota transplantation for patients with chronic pouchitis: A case series. Clin Case Rep. 2019;7:782-8. doi: 10.1002/ccr3.2096. PubMed PMID: 30997086; PubMed Central PMCID: PMCPMC6452488.
  109. Hoffman S, Aviv Cohen N, Carroll IM, Tulchinsky H, Borovok I, Dotan I, et al. Faecal Proteases from Pouchitis Patients Activate Protease Activating Receptor-2 to Disrupt the Epithelial Barrier. J Crohns Colitis. 2019;13:1558-68. doi: 10.1093/ecco-jcc/jjz086. PubMed PMID: 31056700.
  110. Kousgaard SJ, Nielsen HL, Kirk KF, Thorlacius-Ussing O. Faecal microbiota transplantation to chronic pouchitis improves quality of life: a pilot study. Int J Colorectal Dis. 2020;35:2135-6. doi: 10.1007/s00384-020-03677-w. PubMed PMID: 32583041.
  111. Cold F, Kousgaard SJ, Halkjaer SI, Petersen AM, Nielsen HL, Thorlacius-Ussing O, et al. Fecal Microbiota Transplantation in the Treatment of Chronic Pouchitis: A Systematic Review. Microorganisms. 2020;8. doi: 10.3390/microorganisms8091433. PubMed PMID: 32962069; PubMed Central PMCID: PMCPMC7565999.
  112. Castano-Rodriguez N, Paramsothy S, Kaakoush NO. Promise of Fecal Microbiota Transplantation Therapy in Pouchitis. Dig Dis Sci. 2020;65:1107-10. doi: 10.1007/s10620-019-05831-z. PubMed PMID: 31529413.
  113. Schieffer KM, Wright JR, Harris LR, Deiling S, Yang Z, Lamendella R, et al. NOD2 Genetic Variants Predispose One of Two Familial Adenomatous Polyposis Siblings to Pouchitis Through Microbiome Dysbiosis. J Crohns Colitis. 2017;11:1393-7. doi: 10.1093/ecco-jcc/jjx083. PubMed PMID: 28633443; PubMed Central PMCID: PMCPMC5881696.
  114. Deepak P, Chebrolu K, Evans B, Ciorba MA. Pouchitis: Bile Acid Deficiency Links Inflammation to Dysbiosis. Gastroenterology. 2020;159:1615-6. doi: 10.1053/j.gastro.2020.08.014. PubMed PMID: 32805282.
  115. Herfarth H, Barnes EL, Long MD, Isaacs KL, Leith T, Silverstein M, et al. Combined Endoscopic and Oral Fecal Microbiota Transplantation in Patients with Antibiotic-Dependent Pouchitis: Low Clinical Efficacy due to Low Donor Microbial Engraftment. Inflamm Intest Dis. 2019;4:1-6. doi: 10.1159/000497042. PubMed PMID: 31172007; PubMed Central PMCID: PMCPMC6537468.
  116. Selvig D, Piceno Y, Terdiman J, Zydek M, Umetsu SE, Balitzer D, et al. Fecal Microbiota Transplantation in Pouchitis: Clinical, Endoscopic, Histologic, and Microbiota Results from a Pilot Study. Dig Dis Sci. 2020;65:1099-106. doi: 10.1007/s10620-019-05715-2. PubMed PMID: 31302808.
  117. Minhas HJ, Papamichael K, Cheifetz AS, Gianotti RJ. A primer on common supplements and dietary measures used by patients with inflammatory bowel disease. Ther Adv Chronic Dis. 2023;14:20406223231182367. doi: 10.1177/20406223231182367. PubMed PMID: 37426698; PubMed Central PMCID: PMCPMC10328183.
  118. Ng JY, Liu H, Wang MC. Complementary and alternative medicine mention and recommendations in inflammatory bowel disease guidelines: systematic review and assessment using AGREE II. BMC Complement Med Ther. 2023;23:230. doi: 10.1186/s12906-023-04062-0. PubMed PMID: 37434218; PubMed Central PMCID: PMCPMC10334672.
  119. Matsuoka H, Uchino M, Horio Y, Sasaki H, Chohno T, Hirata A, et al. The Use of Oral Herbal Medicine (Hange-Shashin-To) in Patients with Pouchitis: A Pilot Study. J Anus Rectum Colon. 2018;2:9-15. doi: 10.23922/jarc.2017-015. PubMed PMID: 31583317; PubMed Central PMCID: PMCPMC6768822.
  120. Mehta M, Ahmed S, Dryden G. Refractory pouchitis improves after administration of the green tea polyphenol EGCG: a retrospective review. Int J Colorectal Dis. 2018;33:83-6. doi: 10.1007/s00384-017-2906-5. PubMed PMID: 28929216.
آمار
تعداد مشاهده مقاله: 265
تعداد دریافت فایل اصل مقاله: 241


سامانه مدیریت نشریات علمی. قدرت گرفته از سیناوب